[바이오사 리포트] 차바이오텍, 1Q 손실 확대…신사업 투자 회수 과제

Cha Biotech's Q1 2026 results highlight a pivotal challenge for its multi-platform strategy: operating losses widened despite 8.4% revenue growth as investments in AI healthcare and NK cell therapies created a cost-revenue mismatch. Market attention now centers on whether these capital-intensive initiatives—particularly CAR-NK cell therapy commercialization and AI-powered digital healthcare platforms—can generate operating leverage by Q2 2026. This case exemplifies a persistent biotech sector puzzle: scaling innovative cell therapies while demonstrating near-term financial returns to satisfy investor discipline.